All Oncology News

The Breast Cancer Index test reliably identified premenopausal women undergoing adjuvant endocrine therapy for early-stage, hormone receptor–positive breast cancer who would derive benefit from the addition of ovarian function suppression.

With patents expiring on some of the revolutionary agents in cancer treatment, the emergence of biosimilars as a lower-cost option has seen exponential growth.

Sameek Roychowdhury, MD, PhD, discusses the rationale for targeting FGFR mutations in cholangiocarcinoma and urothelial carcinoma, the potential efficacy of irreversible pan-FGFR inhibitors in these populations, and how continued research in this area may yield more personalized therapeutic approaches for patients with FGFR mutations.

Non-Hispanic Black patients with hormone receptor–positive/HER2-negative breast cancer were more likely to have worse outcomes vs non-Hispanic White, Asian, and Hispanic patients, according to an analysis of the phase 3 RxPONDER trial.

The addition of 1 year of everolimus to adjuvant endocrine therapy did not demonstrate a statistically significant improvement in invasive disease-free survival or overall survival in patients with high-risk, hormone receptor–positive, HER2-negative breast cancer.

The combination of ribociclib plus endocrine therapy yielded a 46% reduction in the risk of disease progression or death compared with chemotherapy in pre/perimenopausal patients with aggressive hormone receptor–positive/HER2-negative advanced breast cancer.

Chemotherapy prior to treatment with endocrine therapy could increase the risk of cancer-related cognitive impairment compared with endocrine therapy alone in women with breast cancer, irrespective of menopausal status.

Tumor microenvironment of metastasis doorway density—a biomarker of distant metastatic recurrence—is higher in Black women vs White women with estrogen receptor–positive/HER2-negative breast cancer who have residual disease after neoadjuvant chemotherapy.

The development of zandelisib for the treatment of B-cell malignancies has been discontinued outside of Japan.

More than 160 attendees took part in a day of learning and collaboration as Sylvester Comprehensive Cancer Center hosted the inaugural Cancer Survivorship Symposium.

Researchers from Dana-Farber Cancer Institute will present more than 30 research studies at the 44th annual San Antonio Breast Cancer Symposium on December 7-10th.

The FDA has granted a breakthrough therapy designation to revumenib for the treatment of adult and pediatric patients with relapsed/refractory acute leukemia harboring a KMT2A rearrangement.

As new classes of agents deliver promising results for patients with HER2-mutant non–small cell lung cancer, new questions surrounding optimal identification tactics, sequencing, and treatment of patients arise.

The addition of budigalimab to ABBV-151 was well tolerated and significantly enhanced responses in patients with locally advanced or metastatic solid tumors.

Erika P. Hamilton, MD, discusses anticipated updates from DESTINY-Breast02 and DESTINY-Breast03 that will be presented at the 2022 San Antonio Breast Cancer Symposium, how trastuzumab emtansine will fit into the armamentarium in light of the efficacy of trastuzumab deruxtecan, and additional data to expect from SABCS regarding ADCs and beyond.

Building on research his father conducted decades earlier, Robert Orlowski, MD, PhD, redefined myeloma treatment.

The combination of neoadjuvant vidutolimod and nivolumab elicited high response rates and was well tolerated in patients with high-risk, resectable melanoma, according to final results from a phase 2 trial.

Enrollment has been paused for a phase 1 trial investigating the peptide-drug conjugate TH1902 for the treatment of patients with sortilin-expressing cancers.

Treatment with lutetium Lu 177 vipivotide tetraxetan led to a statistically significant and clinically meaningful improvement in radiographic progression-free survival following treatment with an androgen receptor pathway inhibitor in patients with prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer.

Florida Cancer Specialists & Research Institute welcomes Board-certified medical oncologist Ke Ning, MD to the Sarasota Downtown clinic team.

For patients with colon cancer, traditional clinical and pathologic risk factors may soon take a backseat as stratification tactics for determining optimal candidates for adjuvant chemotherapy.

The combination of sintilimab and anlotinib elicited improved responses and progression-free survival compared with chemotherapy in previously untreated patients with metastatic non–small cell lung cancer.

Olaparib plus durvalumab and bevacizumab led to prolonged survival and disease control without causing additive toxicity in patients with non-germline BRCA-mutated, platinum-sensitive, relapsed ovarian cancer.

A girl who grew up in a small South Dakota town, Julie M. Vose, MD, MBA, grew into a dynamo who revolutionized lymphoma treatment and led the most prominent oncology organization in the world.

The European Medicines Agency has accepted a marketing authorization application for momelotinib as a treatment for patients with myelofibrosis.

The FDA has issued a complete response letter to the biologics license application seeking the approval of 131I-omburtamab for the treatment of pediatric patients with central nervous system/leptomeningeal metastases from neuroblastoma.

It’s long been known that DNA damage caused by environmental triggers, as well as other sources of oxidative stress, contribute to the development and progression of a wide variety of cancers.

Dostarlimab plus standard-of-care chemotherapy, followed by dostarlimab alone, produced a statistically significant and clinically meaningful improvement in progression-free survival vs chemotherapy alone in patients with primary advanced or recurrent endometrial cancer.

Pharmaceutical manufacturer EQRx announced December 2, 2022, that the European Medicines Agency has accepted a marketing authorization application for the use of aumolertinib in EGFR-mutated non–small cell lung cancer and locally advanced or metastatic EGFR T790M mutation–positive NSCLC.

The FDA has granted an orphan drug designation to AUM302 for the treatment of patients with neuroblastoma.